This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scaltriti, M. Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Scaltriti, M. Articles by Baselga, J.

The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

Authors' Affiliations: ¹ Medical Oncology Service, Vall d'Hebron University Hospital and Universidad Autónoma de Barcelona, Barcelona, Spain and ² Dipartimento di Medicina Sperimentale, Universita' degli Studi di Parma, Parma, Italy

Requests for reprints: José Baselga, Medical Oncology Service, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, Barcelona 08035, Spain. Phone: 34-93-274-6077; Fax: 34-93-274-6059; E-mail: jbaselga{at}vhebron.net.

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.

This article has been cited by other articles:

				T. Moore, L. Beltran, S. Carbajal, S. Strom, J. Traag, S. D. Hursting, and J. DiGiovanni Dietary Energy Balance Modulates Signaling through the Akt/Mammalian Target of Rapamycin Pathways in Multiple Epithelial Tissues Cancer Prevention Research, June 1, 2008; 1(1): 65 - 76. [Abstract] [Full Text] [PDF]

				R. S. Finn Targeting Src in breast cancer Ann. Onc., May 16, 2008; (2008) mdn291v1. [Abstract] [Full Text] [PDF]

				T. L. Johnson, M. B. Lai, J. C. K. Lai, and A. Bhushan Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A Evid. Based Complement. Altern. Med., February 29, 2008; (2008) nen011v1. [Abstract] [Full Text] [PDF]

				J. Krol, R. E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R. C. Coombes, and E. W.-F. Lam The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3169 - 3179. [Abstract] [Full Text] [PDF]

				J. Kim, W. J. Jahng, D. Di Vizio, J. S. Lee, R. Jhaveri, M. A. Rubin, A. Shisheva, and M. R. Freeman The Phosphoinositide Kinase PIKfyve Mediates Epidermal Growth Factor Receptor Trafficking to the Nucleus Cancer Res., October 1, 2007; 67(19): 9229 - 9237. [Abstract] [Full Text] [PDF]